Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study by Chenming Liu, Jintao Chen, Yuxing Liu

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer by Soomin Kim, Jaemoon Koh, Tae Min Kim, Songji Oh, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo

“…We used digital spatial profiling to analyze non-small cell lung carcinomas in 25 patients before and after EGFR tyrosine kinase inhibitor (TKI) treatment, including 14 patients treated with first-line osimertinib, focusing on CD45-positive immune regions and pan-cytokeratin-positive tumor regions. …”
Get full text

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy by Shuai Wang, Yongsen Wang, Xuan Wu, Li Yang, Xiaoju Zhang

“…Abstract Background Non-small cell lung cancer (NSCLC) transforming to small cell lung cancer (SCLC) is one of the mechanisms of resistance to tyrosine kinase inhibitors (TKIs). Cases of NSCLC transforming into SCLC have been discovered. …”
Get full text

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression by Elisa Carouge, Clémence Burnichon, Martin Figeac, Shéhérazade Sebda, Nathalie Vanpouille, Audrey Vinchent, Marie‐José Truong, Martine Duterque‐Coquillaud, David Tulasne, Anne Chotteau‐Lelièvre

“…By using a specific MET tyrosine kinase inhibitor in a humanised hepatocyte growth factor (HGF) mouse model, we also establish that MET activity is required for ETV1/ERG‐mediated tumour growth. …”
Get full text

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma by Li Zhang, Matthew Crocker, Lawrence Fong, Lisa M Coussens, Charles D Lopez, Shamilene Sivagnanam, Meenal Sinha, Brandon Chen, Jaqueline Marquez, Alexander Cheung, Whitney Tamaki, Jacob Stultz, Kendra Todd, Courtney Betts, Madeline J Griffith, Isabelle Solman, Eric Liu, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Margaret Tempero

Get full text

Using In Silico Methods to Identify Protein Tyrosine Kinase A (PtkA) Homolog in Non-Tuberculous Mycobacteria (NTM) by Swati Jaiswal, Sanjay Kumar

Subjects: Get full text

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy by Yeonjung Yoon, Hyun Young Park, Min Kyung Chae, Sun Young Jang, Jin Sook Yoon

Subjects: “…interleukin-2 inducible tyrosine kinase…”
Get full text

Tyrosine Kinase Inhibitor-Induced Intracranial Artery Stenosis – A Rare Cause of TIA in a Patient of Chronic Myeloid Leukemia by Sumedh S Agrawal, Nikith A Shetty, Nisha Shenoy, Arvind N Prabhu, Aparna R Pai

Get full text

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib by Vineeth Sukrithan, Lisa Kim, Jennifer A. Sipos, Ashima Goyal, Ye Zhou, Daniel Addison, Manisha Shah, Bhavana Konda, Ajay Vallakati

“…The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid cancers compared to placebos. …”
Get full text

Tyrosine Kinase-2, Angiopoietin-2, and Thrombomodulin Axes in the Late-Onset Fetal Growth Restriction: A Prospective Cohort Study by Esra Altan Erbilen, Fusun Gulizar Varol

Subjects: Get full text

Retraction: X-linked immunodeficient mice with no functional Bruton’s tyrosine kinase are protected from sepsis-induced multiple organ failure by Frontiers Editorial Office

Get full text

Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma by Yuxuan Song, Yiqing Du, Shan Jiang, Yun Peng, Xing Luo, Tao Xu

“…Selective pan-FGFR tyrosine kinase inhibitor (FGFRi) has been approved for FGFR-altered UC. …”
Get full text

Activating Mutation (V617F) in the Tyrosine Kinase JAK2 is Absent in Locally-Confined or Castration-Resistant Prostate Cancer by Lei Gu, Xian-Hua Zhu, Tapio Visakorpi, Kalle Alanen, Tuomas Mirtti, Tina Bocker Edmonston, Marja T. Nevalainen

“…The receptor-associated tyrosine kinase Jak2 is a known key activator of Stat5a/b in prostate cancer cells in response to ligand stimulation. …”
Get full text

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3 by Alexander J. D. Snow, Tharushi Wijesiriwardena, Benjamin J. Lane, Brendan Farrell, Polly C. Dowdle, Matilda Katan, Stephen P. Muench, Alexander L. Breeze

“…The inherent enzymatic activity of receptor tyrosine kinases (RTKs) presents additional challenges. …”
Get full text

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax by Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Abdessamad A. Youssfi, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony J. Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz

“…Here, we build on recent findings implicating gain-of-function mutations in the BCL10 signaling protein as drivers of resistance to Bruton’s tyrosine kinase (BTK) inhibitors. We show mutant BCL10-driven DLBCL is resistant to multiple additional drug classes, demonstrating urgency to derive mechanistically rooted strategies to overcome undruggable BCL10 mutants that stabilize BTK-independent signaling filaments upstream of NF-kB activation. …”
Get full text

Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia by Carmen Rădulescu, Anca Bacârea, Adina Huțanu, Rozalia Gabor, Minodora Dobreanu

Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

Subjects: Get full text

An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia by Mahmoud Fathy Hassan, Nancy Mohamed Ali Rund, Ahmed Husseiny Salama

Get full text

Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study by Matteo Dragani, Michela Ansuinelli, Cristina Papayannidis, Nicola Fracchiolla, Valeria Cardinali, Michele Cedrone, Fabio Guolo, Salvatore Perrone, Prassede Salutari, Elisabetta Todisco, Robin Foà, Sabina Chiaretti

Get full text

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience by Idanna Innocenti, Antonio Mosca, Annamaria Tomasso, Andrea Galitzia, Lydia Scarfò, Francesca Morelli, Eugenio Galli, Francesca Martini, Eugenio Sangiorgi, Roberta Laureana, Giulia Benintende, Veronica Mattiello, Sabrina Chiriu, Maria I. Del Principe, Giulia Zamprogna, Massimo Gentile, Enrica A. Martino, Emilia Cappello, Maria C. Montalbano, Giuliana Farina, Vanessa Innao, Luca Stirparo, Caterina Patti, Paolo Sportoletti, Alberto Fresa, Gioacchino Catania, Marta Coscia, Silvia Bellesi, Alessandra Tedeschi, Alessandro Sanna, Andrea Visentin, Francesco Autore, Raffaella Pasquale, Livio Trentin, Marzia Varettoni, Paolo Ghia, Roberta Murru, Luca Laurenti

Get full text